Inhibition of Activated Coagulation Factor VII by Normal Human Plasma

P E Dahl; U Abildgaard; M L Larsen; L Tjensvoll

doi:10.1055/s-0038-1657273

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1982; 48(03): 253-256
DOI: 10.1055/s-0038-1657273

Original Article

Schattauer GmbH Stuttgart

Inhibition of Activated Coagulation Factor VII by Normal Human Plasma

P E Dahl

The Haematological Laboratory, Medical Department A, Aker Hospital, Oslo, Norway

,

U Abildgaard

The Haematological Laboratory, Medical Department A, Aker Hospital, Oslo, Norway

,

M L Larsen

The Haematological Laboratory, Medical Department A, Aker Hospital, Oslo, Norway

,

L Tjensvoll

The Haematological Laboratory, Medical Department A, Aker Hospital, Oslo, Norway

› Author Affiliations

Abstract

PDF Download

Summary

An amidolytic assay system with tissue thromboplastin (Tpl), purified coagulation factors VII and X, and the chromogenic substrate S-2222 was developed. Antithrombin III (AT) accounts for about one third of the total inhibition exerted by normal plasma in this test system. This effect of AT was prevented by adding purified AT blocking antibodies. Normal plasma and serum showed approximately similar inhibitory effects. The inhibition was probably directed against activated factor VII (F VIIa). Gel filtration of adsorbed normal plasma on Ultrogel AcA 34 showed three inhibitory peaks which were different from AT.

Keywords

Key words Factor VII - Coagulation inhibitors - Chromogenic substrates

PDF (778 kb)

References

References
1 Hjort PF. Intermediate reactions in the coagulation of blood with tissue thromboplastin. Scand J Clin Lab Invest 1957; 9 (Suppl. 27) 1-183
2 Prydz H, Allison AC. Tissue thromboplastin activity of isolated human monocytes. Thromb Haemostas 1978; 39: 582-591
3 Aas K. Prokonvertin og konvertin. Thesis. Oslo Akad trykningssentral. 1952: 90
4 Wagner RH, Brannan jr WM, Brinkhous KM. Antiaccelerator (Anticonvertin) Activity of Canine Plasma and Serum. Proc Soc Exp Biol Med 1955; 89: 266-269
5 Egeberg O. On the Natural Blood Coagulation Inhibitor System – Investigations of Inhibitor Factors Based on Antithrombin Deficient Blood. Thrombos Diathes Haemorrh 1965; 14: 473-489
6 Godal HC, Rygh M, Laake K. Progressive inactivation of purified factor VII heparin and antithrombin III. Throinb Res 1974; 5: 773-775
7 Østerud B, Miller-Andersson M, Abildgaard U, Prydz H. The Effect of Antithrombin III on the Activity of the Coagulation Factors VII, IX and X. Thromb Haemostas 1976; 35: 295-304
8 Harboe N, Ingild A. Immunization Isolation of Immunglobulins, Estimation of Antibody Titre. Scand J Immunol 1933; 2 (Suppl. 01) 161
9 Hvatum M, Prydz H. Studies on tissue thromboplastin I. Solubilization with deoxycholate. Biochim Biophys Acta 1966; 130: 92-101
10 Laake K, Ellingsen R. Purification and some characteristics of factor VII in human titrated plasma, glass-activated serum, and cold-activated plasma. Thromb Res 1974; 5: 539-556
11 Aurell L, Friberger P. Determination of Factor X in plasma with S-2222. Laboratory Instruction. Kabi Diagnostica. 1977
12 Gladhaug A, Prydz H. Purification of the coagulation factors VII and X from human serum. Some properties of factor VII. Biochim Biophys Acta 1970; 215: 105-111
13 Abildgaard U, Lie M, Ødegård OR. Antithrombin (heparin cofactor) assay with “new” chromogenic substrates (S-2238 and Chromozym-TH). Thromb Res 1977; 11: 749-553
14 Nemerson Y. Biological Control of Factor VII. Thromb Haemostas 1976; 35: 96-100
15 Hermansky F, Vitek J. The Role of Proconvertin and Stuart Factor in the Inactivation of Tissue Thromboplastin by Serum. Experientia 1960; 16: 455-456
16 Seligsohn U, Østerud B, Rapaport SI. Coupled Amidolytic Assay for Factor VII: Its Use with a Clotting Assay to Determine the Activity State of Factor VII. Blood 1978; 52 (05) 978-988
17 Østerud B, Rapaport SI. Activation of Factor IX by the Reaction Product of Tissue Factor and Factor VII: Additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-5264